Asthma and Allergy Markets
Currently the only systemic delivery option is inhalation
- Limits cromolyn’s efficacy due to high variability and low systemic delivery efficiency
A better method of delivery is still needed
- Patients would benefit from increased systemic levels
Unique opportunity to expand an underserved market
- Oral delivery affords a higher bioavailability and thus higher systemic levels, resulting in increased delivery efficiency as compared to inhalation